drugset / Trial / NCT00616213

PR104 and G-CSF in Treating Patients With Solid Tumors

NCT00616213

Phase 1 Completed 5 enrolled Proacta, Incorporated
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving PR-104 together with G-CSF may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given together with G-CSF in treating patients with solid tumors.

Timeline

Start
2008-02
Primary completion
2008-09
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PR104 Small molecule Intravenous
Background filgrastim Protein / enzyme biologic